FMX 2025: 6 Takeaways for Primary Care Physicians
Explore key clinical takeaways from FMX 2025, including updates on CGM, chronic cough, AAA screening, immunization, and more.
Hormone Therapy and Autoimmune Disease: Early Findings Raise New Questions for Postmenopausal Care
New research suggests hormone therapy may increase autoimmune disease risk in postmenopausal women. Dr Jiang discusses early findings and clinical implications.
Xuezhi Daniel Jiang, MD, PhD, on Counseling Postmenopausal Women on Autoimmune Disease Risk Without Creating Hormone Therapy Phobia
Jiang shares how to use new autoimmune risk data responsibly—identifying high-risk patients while avoiding unnecessary hormone therapy phobia.
Perimenopause Symptom Management is Never One-Size-Fits-All, Says Menopause Expert
TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"
Perimenopausal Brain Fog: A Frequent Complaint That Needs a Compassionate Response, Says Marla Shapiro, CM, CCFP, MHSc
"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.
Quiz: Recent Advances in Menopause and Midlife Women’s Health Research
A quick quiz covering new research on menopause hormone therapy, Alzheimer risk, tirzepatide weight loss, and estetrol’s cardiovascular safety.
Genitourinary Syndrome of Menopause (GSM): Clinical FAQ for Primary Care
Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.
Screening for Breast Cancer in Patients With Dense Breast Tissue: A Q&A With Donna Plecha, MD
TMS 2025: Donna Plecha, MD, discusses how primary care physicians should approach breast cancer screening in women with dense breasts and use MRI effectively.
TMS 2025: Regina Castaneda, MD, on Tirzepatide, Menopause, and Hormone Therapy
Inequities in MHT Prescribing Run Deep: A Conversation With Wake Forest's Anna Caroline Cochrane, MD
TMS 2025: Cochrane explains the impetus behind 2 studies she has authored on the patient- and provider-level factors that influence MHT prescribing.
Mayo Clinic Researcher on How Hormone Therapy May Influence Weight Loss Outcomes With Tirzepatide
Brain Changes, Weight Management, and Breast Screening: Essential Updates From TMS 2025
New research from TMS 2025 covers menopause effects on brain volume, hormone therapy's role in weight loss with GLP-1s, and dense breast screening updates.
MHT and Alzheimer Risk: New Evidence for a Critical Window, with Roksana Karim, MD, PhD
Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.
Why Do Women Suffer in Silence with Genitourinary Syndrome of Menopause?
Menopause specialist Caroline Mitchell, MD, MPH, explains the dual nature of the breakdown in communication that can leave women virtually uninformed about GSM and treatment.
Hormone Therapy Linked to Increased Autoimmune Disease Risk
Dr. Daniel Jiang shares unexpected research findings showing hormone therapy increased autoimmune disease risk across 15 of 17 conditions in postmenopausal women.
Hormone Therapy and Autoimmune Disease Risk in Postmenopausal Women, With Xuezhi Daniel Jiang, MD, PhD
TMS 2025: Jiang explains why he investigated hormone therapy's effect on autoimmune disease risk in postmenopausal women.
Estetrol Phase 3 Trial Shows No Impact on Postmenopausal BP, Even in Women at High CV Risk
The phase 3 E4COMFORT II trial found no impact on BP after 1 year of treatment in postmenopausal women with elevated HbA1c, lipids, and TGs.
Caroline Mitchell, MD, Describes Toll of Genitourinary Syndrome of Menopause on QoL
TMS: Half of postmenopausal women suffer from GSM, yet only 25% seek treatment. Mitchell, an expert in vulvovaginal health, explains the gap and its impact on women.
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.
Menopause: A Constellation of Syndromes Across 13 Body Systems
Our short slide show outlines interrelated syndromes of menopause across 13 body systems, implicating therapeutic targets and approaches for clinical practice.
